LSE - Delayed Quote GBp

Allergy Therapeutics plc (AGY.L)

Compare

4.8800

-0.1200

(-2.40%)

At close: 4:35 PM GMT+1

Currency in GBP All numbers in thousands

Download

Breakdown

TTM

6/30/2023

6/30/2022

6/30/2021

6/30/2020

Total Revenue

53,258.0000

59,587.0000

72,768.0000

84,331.0000

78,204.0000

Cost of Revenue

25,276.0000

26,342.0000

23,262.0000

22,106.0000

20,201.0000

Gross Profit

27,982.0000

33,245.0000

49,506.0000

62,225.0000

58,003.0000

Operating Expense

66,819.0000

68,149.0000

61,751.0000

58,194.0000

49,694.0000

Operating Income

-38,837.0000

-34,904.0000

-12,245.0000

4,031.0000

8,309.0000

Net Non Operating Interest Income Expense

-4,899.0000

-2,112.0000

-412.0000

-374.0000

-238.0000

Pretax Income

-48,482.0000

-41,766.0000

-12,657.0000

3,657.0000

8,071.0000

Tax Provision

1,734.0000

1,305.0000

1,119.0000

771.0000

1,013.0000

Net Income Common Stockholders

-50,216.0000

-43,071.0000

-13,776.0000

2,886.0000

7,058.0000

Diluted NI Available to Com Stockholders

-50,216.0000

-43,071.0000

-13,776.0000

2,886.0000

7,058.0000

Basic EPS

-0.06

-0.08

-0.02

0.00

0.01

Diluted EPS

-0.06

-0.08

-0.02

0.00

0.01

Basic Average Shares

1,699,664.5000

670,355.0000

642,990.0000

639,190.0000

636,169.0000

Diluted Average Shares

1,699,664.5000

670,355.0000

684,076.0000

676,658.0000

673,492.0000

Total Operating Income as Reported

-43,583.0000

-39,654.0000

-12,245.0000

4,031.0000

8,309.0000

Total Expenses

92,095.0000

94,491.0000

85,013.0000

80,300.0000

69,895.0000

Net Income from Continuing & Discontinued Operation

-50,216.0000

-43,071.0000

-13,776.0000

2,886.0000

7,058.0000

Normalized Income

-46,371.7400

-39,223.5000

-13,776.0000

2,886.0000

7,058.0000

Interest Income

333.0000

329.0000

254.0000

107.0000

261.0000

Interest Expense

5,232.0000

2,441.0000

669.0000

491.0000

504.0000

Net Interest Income

-4,899.0000

-2,112.0000

-412.0000

-374.0000

-238.0000

EBIT

-43,250.0000

-39,325.0000

-11,988.0000

4,148.0000

8,575.0000

EBITDA

-39,014.0000

-35,101.0000

-7,822.0000

8,280.0000

12,489.0000

Reconciled Cost of Revenue

25,276.0000

26,342.0000

23,262.0000

22,106.0000

20,201.0000

Reconciled Depreciation

4,236.0000

4,224.0000

4,166.0000

4,132.0000

3,914.0000

Net Income from Continuing Operation Net Minority Interest

-50,216.0000

-43,071.0000

-13,776.0000

2,886.0000

7,058.0000

Total Unusual Items Excluding Goodwill

-4,746.0000

-4,750.0000

Total Unusual Items

-4,746.0000

-4,750.0000

Normalized EBITDA

-34,268.0000

-30,351.0000

-7,822.0000

8,280.0000

12,489.0000

Tax Rate for Calcs

0.0002

0.0001

Tax Effect of Unusual Items

-901.7400

-902.5000

6/30/2020 - 10/11/2004

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

NUTEX.BD NUTEX Investments Public Limited Company

19.30

-0.26%

ANA.AQ Ananda Developments Plc

0.3475

+24.11%

PNXP Pineapple Express Cannabis Company

0.1601

-83.83%

ATB.RO Antibiotice S.A.

3.1300

0.00%

RGT.L Argent BioPharma Limited

19.50

0.00%

PPGN.SW PolyPeptide Group AG

28.75

-1.03%

BXP.L Beximco Pharmaceuticals Limited

30.00

-6.25%

STX.L Shield Therapeutics plc

4.6000

0.00%

0QFP.IL Richter Gedeon Vegyészeti Gyár Nyilvánosan Muk?do Rt.

5,040.00

0.00%

EAPI.PA Euroapi S.A.

3.2860

+1.29%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Allergy Therapeutics plc (AGY.L)

Upgrade to begin using 40 years of financial statements and get so much more.

Related Tickers